Exposure‐Safety Analyses Identify Predictors of Change in Bone Mineral Density and Support Elagolix Labeling for Endometriosis‐Associated Pain

Elagolix is a novel oral gonadotropin releasing hormone receptor antagonist, that can suppress estradiol in a dose‐dependent manner. It is indicated for management of moderate‐to‐severe pain associated with endometriosis. A population exposure‐response model describing the relationship between elago...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:CPT Pharmacometrics Syst Pharmacol
Autori principali: Abbas Suleiman, Ahmed, Nader, Ahmed, Winzenborg, Insa, Beck, Denise, Polepally, Akshanth R., Ng, Juki, Noertersheuser, Peter, Mostafa, Nael M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2020
Soggetti:
Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7679073/
https://ncbi.nlm.nih.gov/pubmed/32945631
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/psp4.12560
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi